Ajai Chari, MD
Hematology/Oncology · Berkeley
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 5
- Since medical school
- 27 years
- University of California, Geffen School of Medicine, 1999
Offices
5 locations · UCSF Medical Group Business Services · University of California San Francisco · Regents of the University of California
Hospitals listed: Mount Sinai Hospital · UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chari’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Mount Sinai HospitalNew York, NYAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Mount Sinai Health System, which runs 5 hospitalsHome of Tisch Cancer Institute, a National Cancer Institute designated cancer centrePatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.9 (11 to 15) · 878 cases, Jan 2024 – Dec 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.473, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.513, Oct 2024 – Sep 2025Better than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 3.9 (3 to 5.1) · 878 cases, Jan 2024 – Dec 2024
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Mount Sinai Hospital
Behind the star rating — Deaths: 4 better, 4 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 1 worse of 8 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.9 (11 to 15) · 878 cases | Worse | Jan 2024 – Dec 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.473 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.513 | Better | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 3.9 (3 to 5.1) · 878 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.56 (0.9 to 2.21) · 4,503 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.03 (0.88 to 1.18) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 172.14 (136.78 to 207.5) · 260 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.4 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.6 · 168 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.1 · 139 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.9 · 785 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.4 · 774 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.8 · 589 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.2 · 10,714 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.08 (0 to 0.24) · 19,045 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.36 (0.21 to 0.52) · 20,760 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.47 (3.23 to 5.72) · 7,869 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.36 (0.41 to 2.3) · 3,840 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.62 (0.77 to 2.47) · 7,428 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.64 (5.02 to 10.27) · 3,845 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.23 (2.36 to 6.09) · 4,008 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.19 (0 to 2.45) · 1,428 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.93 (0.63 to 1.23) · 15,577 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.7 · 621 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.718 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.654 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.779 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.813 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.2 · 385 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.9 · 1,625 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.7 · 236 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 21.5 · 883 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 37.6 · 760 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.6 · 1,228 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.2 · 669 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 184 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 371 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.3 to 16.1) · 681 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 1,157 cases | No different | Jan 2024 – Dec 2024 |
What patients said (799 patients answered, 16% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$140,537
Medicare paid this office $140,537 for 138 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 108 | $30,460 | $121 |
| New patient visit (60+ min) | 46 | $6,566 | $143 |
| Return visit (30+ min) | 49 | $4,715 | $77 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 110 | $3,084 | $15 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 23 | $1,459 | $63 |
See all 6 services
| Long return visit (40+ min) | 108 | $30,460 | $121 |
| New patient visit (60+ min) | 46 | $6,566 | $143 |
| Return visit (30+ min) | 49 | $4,715 | $77 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 110 | $3,084 | $15 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 23 | $1,459 | $63 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 21 | $837 | $28 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy and aspiration of bone marrow sample for diagnosis | – | – | – | – | – | 23 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
138 Original Medicare patients in 2024. Average age 73 · Women 45% · Also on Medicaid 16% · Health risk score 2.75. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 69% · Chronic kidney disease 41% · Diabetes 22% · Heart failure 20% · Coronary heart disease 17% · Atrial fibrillation 17% · Depression 17% · Cancer 13% · COPD 9%.
The office billed $1,179,345, Medicare allowed $180,699 and paid $140,537; for 2,773 services of 28 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 138 | 2,773 | 73 | 2.75 | $1,179,345 | $140,537 |
| 2023 | 152 | 177 | 74 | 3.33 | $178,216 | $15,707 |
| 2022 | 222 | 730 | 73 | 2.97 | $307,369 | $71,413 |
| 2021 | 203 | 723 | 72 | 2.90 | $290,970 | $73,398 |
| 2020 | 198 | 636 | 73 | 3.37 | $240,954 | $50,880 |
| 2019 | 215 | 830 | 71 | 3.64 | $279,749 | $81,239 |
| 2018 | 216 | 1,107 | 71 | 3.51 | $329,261 | $122,179 |
| 2017 | 178 | 948 | 70 | 3.58 | $259,387 | $98,160 |
| 2016 | 192 | 888 | 70 | 3.33 | $231,150 | $83,424 |
| 2015 | 163 | 618 | 71 | 2.73 | $185,700 | $51,658 |
| 2014 | 150 | 531 | 69 | 2.97 | $159,175 | $42,403 |
| 2013 | 151 | 639 | 69 | 2.66 | $183,400 | $44,255 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Long return visit (40+ min) | 65 | $8,037 | $113 |
| Return visit (30+ min) | 30 | $2,012 | $65 |
| Return visit (30+ min) | 27 | $1,836 | $68 |
| Long return visit (40+ min) | 13 | $1,356 | $97 |
2022: 10 services
| Long return visit (40+ min) | 60 | $14,827 | $128 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $11,897 | $94 |
| Return visit (30+ min) | 81 | $11,254 | $82 |
| Long return visit (40+ min) | 54 | $10,745 | $119 |
| Return visit (30+ min) | 72 | $9,598 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,494 | $64 |
| New patient visit (60+ min) | 15 | $2,482 | $165 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,320 | $178 |
| Short return visit (20+ min) | 21 | $1,400 | $56 |
| Short return visit (20+ min) | 12 | $849 | $61 |
2021: 11 services
| Long return visit (40+ min) | 63 | $14,706 | $140 |
| Return visit (30+ min) | 78 | $11,731 | $93 |
| Return visit (30+ min) | 74 | $10,552 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $10,450 | $96 |
| Long return visit (40+ min) | 46 | $10,237 | $135 |
| New patient visit (60+ min) | 21 | $3,512 | $167 |
| Short return visit (20+ min) | 27 | $2,029 | $60 |
| Telephone medical discussion with physician, 21-30 minutes | 26 | $1,881 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,803 | $67 |
| Short return visit (20+ min) | 19 | $1,284 | $64 |
| Telephone medical discussion with physician, 11-20 minutes | 13 | $718 | $55 |
2020: 12 services
| Long return visit (40+ min) | 67 | $8,960 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $8,232 | $97 |
| Long return visit (40+ min) | 40 | $6,449 | $106 |
| Return visit (30+ min) | 57 | $5,766 | $74 |
| Return visit (30+ min) | 65 | $5,159 | $59 |
| Telephone medical discussion with physician, 21-30 minutes | 28 | $2,364 | $72 |
| Telephone medical discussion with physician, 21-30 minutes | 28 | $2,211 | $71 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $2,081 | $67 |
| Telephone medical discussion with physician, 11-20 minutes | 30 | $1,491 | $48 |
| Telephone medical discussion with physician, 11-20 minutes | 13 | $772 | $48 |
| Short return visit (20+ min) | 15 | $720 | $45 |
| Short return visit (20+ min) | 13 | $580 | $41 |
2019: 7 services
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 41 | $25,088 | $157 |
| Long return visit (40+ min) | 102 | $21,419 | $96 |
| Return visit (30+ min) | 119 | $14,601 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $9,391 | $94 |
| New patient visit (60+ min) | 25 | $3,515 | $141 |
| Short return visit (20+ min) | 38 | $2,265 | $46 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,853 | $64 |
2018: 7 services
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 79 | $69,933 | $157 |
| Long return visit (40+ min) | 85 | $17,630 | $94 |
| Return visit (30+ min) | 99 | $12,970 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $10,480 | $93 |
| New patient visit (60+ min) | 28 | $4,093 | $146 |
| Short return visit (20+ min) | 51 | $2,958 | $40 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,945 | $65 |
2017: 9 services
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 59 | $47,040 | $157 |
| Long return visit (40+ min) | 69 | $13,767 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $13,027 | $89 |
| Return visit (30+ min) | 87 | $12,934 | $65 |
| New patient visit (60+ min) | 19 | $2,873 | $151 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,343 | $180 |
| Short return visit (20+ min) | 33 | $2,055 | $43 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,470 | $61 |
| Short return visit | 14 | $318 | $23 |
2016: 10 services
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 37 | $29,635 | $157 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $14,519 | $92 |
| Long return visit (40+ min) | 65 | $12,758 | $96 |
| Return visit (30+ min) | 88 | $12,570 | $68 |
| Biopsy of bone marrow | 44 | $3,174 | $68 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,513 | $180 |
| New patient visit (60+ min) | 15 | $2,264 | $151 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,842 | $64 |
| Short return visit (20+ min) | 34 | $1,798 | $44 |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 44 | $368 | $8 |
2015: 9 services
| Long return visit (40+ min) | 85 | $22,489 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $11,363 | $92 |
| Return visit (30+ min) | 41 | $4,531 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $3,648 | $64 |
| New patient visit (60+ min) | 23 | $3,454 | $150 |
| Biopsy of bone marrow | 26 | $1,909 | $68 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,239 | $95 |
| Short return visit (20+ min) | 11 | $535 | $45 |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 26 | $220 | $8 |
2014: 9 services
| Return visit (30+ min) | 68 | $11,734 | $66 |
| Long return visit (40+ min) | 56 | $10,864 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $9,836 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,308 | $178 |
| New patient visit (60+ min) | 16 | $2,240 | $140 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,867 | $60 |
| Short return visit (20+ min) | 19 | $807 | $38 |
| Biopsy of bone marrow | 13 | $804 | $62 |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 13 | $93 | $7 |
2013: 8 services
| Return visit (30+ min) | 90 | $14,983 | $62 |
| Long return visit (40+ min) | 61 | $9,767 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $8,581 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $2,784 | $61 |
| Biopsy of bone marrow | 32 | $2,083 | $63 |
| New patient visit (60+ min) | 11 | $1,449 | $132 |
| Short return visit (20+ min) | 16 | $805 | $42 |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 31 | $230 | $7 |
Medicaid work
$6,830 in 2024
Medicaid paid $6,830 for 34 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 34 | $6,830 |
| 2024 | 34 | 1 | 14 | $6,830 |
Drugs they prescribed that Part D paid
$2,105,534
Pharmacies billed $2,105,534 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
135 generic and 101 brand-name prescriptions · $2,105,534 in drug cost · 17 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Revlimid | 75 | $1,380,130 | $18,402 |
| Lenalidomide | 30 | $423,140 | $14,105 |
| Acyclovir | 28 | $336 | $12 |
Year by year
| 2024 | 236 | 56 | None | 43% | $2,105,534 |
| 2023 | 190 | 65 | 0% (0) | None | $505,476 |
| 2022 | 511 | 96 | None | None | $269,265 |
| 2021 | 783 | 106 | None | None | $2,028,158 |
| 2020 | 922 | 109 | 0% (0) | 33% | $2,441,725 |
| 2019 | 757 | 116 | None | None | $1,146,564 |
| 2018 | 851 | 112 | 0% (0) | 30% | $1,526,724 |
| 2017 | 555 | 85 | None | 36% | $995,897 |
| 2016 | 404 | 66 | None | None | $469,251 |
| 2015 | 210 | 57 | 7% (14) | 19% | $104,599 |
| 2014 | 317 | 70 | 4% (14) | 16% | $58,339 |
| 2013 | 290 | 55 | 5% (13) | 13% | $66,840 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Revlimid | 13 | $249,866 | $19,220 |
| Acyclovir | 76 | $716 | $9 |
| Valacyclovir | 16 | $643 | $40 |
| Prednisone | 21 | $67 | $3 |
2022: 10 drugs
| Xarelto | 24 | $18,479 | $770 |
| Entecavir | 36 | $14,436 | $401 |
| Eliquis | 15 | $10,902 | $727 |
| Acyclovir | 200 | $2,201 | $11 |
| Valacyclovir | 35 | $1,497 | $43 |
| Pantoprazole | 13 | $504 | $39 |
| Dexamethasone | 16 | $279 | $17 |
| Gabapentin | 21 | $247 | $12 |
| Hydrocortisone | 14 | $187 | $13 |
| Prednisone | 29 | $83 | $3 |
2021: 14 drugs
| Venclexta | 56 | $725,317 | $12,952 |
| Ninlaro | 52 | $593,391 | $11,411 |
| Mozobil | 12 | $328,086 | $27,340 |
| Zarxio | 24 | $67,516 | $2,813 |
| Entecavir | 43 | $20,981 | $488 |
| Xarelto | 18 | $14,458 | $803 |
| Eliquis | 11 | $5,569 | $506 |
| Acyclovir | 229 | $2,773 | $12 |
| Valacyclovir | 35 | $1,631 | $47 |
| Dexamethasone | 76 | $912 | $12 |
| Hydrocortisone | 22 | $430 | $20 |
| Gabapentin | 20 | $133 | $7 |
| Amlodipine Besylate | 11 | $67 | $6 |
| Prednisone | 27 | $59 | $2 |
2020: 17 drugs
| Ninlaro | 101 | $1,086,615 | $10,759 |
| Venclexta | 49 | $608,610 | $12,421 |
| Farydak | 12 | $132,336 | $11,028 |
| Zarxio | 16 | $58,454 | $3,653 |
| Entecavir | 64 | $29,169 | $456 |
| Xarelto | 31 | $20,393 | $658 |
| Eliquis | 18 | $8,874 | $493 |
| Acyclovir | 216 | $2,403 | $11 |
| Dexamethasone | 100 | $1,465 | $15 |
| Doxycycline Hyclate | 11 | $1,235 | $112 |
| Valacyclovir | 31 | $1,067 | $34 |
| Hydrocortisone | 38 | $472 | $12 |
| Ondansetron Odt | 28 | $346 | $12 |
| Prednisone | 37 | $167 | $5 |
| Tamsulosin | 16 | $144 | $9 |
| Pantoprazole | 21 | $112 | $5 |
| Gabapentin | 13 | $103 | $8 |
2019: 15 drugs
| Ninlaro | 43 | $426,313 | $9,914 |
| Farydak | 11 | $99,287 | $9,026 |
| Xarelto | 27 | $13,596 | $504 |
| Entecavir | 24 | $11,359 | $473 |
| Eliquis | 14 | $7,056 | $504 |
| Levocarnitine | 20 | $4,610 | $231 |
| Acyclovir | 191 | $1,528 | $8 |
| Dexamethasone | 78 | $1,220 | $16 |
| Doxycycline Hyclate | 14 | $1,192 | $85 |
| Valacyclovir | 31 | $934 | $30 |
| Hydrocortisone | 36 | $538 | $15 |
| Amlodipine Besylate | 18 | $156 | $9 |
| Gabapentin | 17 | $112 | $7 |
| Pantoprazole | 20 | $105 | $5 |
| Prednisone | 15 | $74 | $5 |
2018: 15 drugs
| Ninlaro | 93 | $907,852 | $9,762 |
| Neupogen | 14 | $69,610 | $4,972 |
| Enoxaparin | 25 | $17,250 | $690 |
| Xarelto | 26 | $14,548 | $560 |
| Doxycycline Hyclate | 27 | $3,435 | $127 |
| Levocarnitine | 13 | $2,082 | $160 |
| Acyclovir | 169 | $1,542 | $9 |
| Dexamethasone | 75 | $1,039 | $14 |
| Valacyclovir | 17 | $849 | $50 |
| Hydrocortisone | 22 | $276 | $13 |
| Levothyroxine | 18 | $233 | $13 |
| Amlodipine Besylate | 28 | $138 | $5 |
| Prednisone | 42 | $128 | $3 |
| Allopurinol | 14 | $111 | $8 |
| Gabapentin | 15 | $102 | $7 |
2017: 11 drugs
| Ninlaro | 48 | $450,847 | $9,393 |
| Venclexta | 17 | $168,716 | $9,924 |
| Xarelto | 24 | $9,704 | $404 |
| Levocarnitine | 15 | $1,496 | $100 |
| Doxycycline Hyclate | 14 | $875 | $63 |
| Acyclovir | 76 | $542 | $7 |
| Hydrocortisone | 25 | $498 | $20 |
| Dexamethasone | 57 | $383 | $7 |
| Pantoprazole | 20 | $160 | $8 |
| Prednisone | 36 | $107 | $3 |
| Amlodipine Besylate | 20 | $61 | $3 |
2016: 8 drugs
| Ninlaro | 27 | $240,133 | $8,894 |
| Acyclovir | 48 | $354 | $7 |
| Dexamethasone | 29 | $299 | $10 |
| Atorvastatin | 22 | $235 | $11 |
| Metoprolol | 15 | $215 | $14 |
| Prednisone | 19 | $93 | $5 |
| Pantoprazole | 13 | $68 | $5 |
| Amlodipine Besylate | 19 | $61 | $3 |
2015: 3 drugs
| Dexamethasone | 16 | $389 | $24 |
| Acyclovir | 33 | $287 | $9 |
| Prednisone | 11 | $87 | $8 |
2014: 5 drugs
| Acyclovir | 52 | $490 | $9 |
| Dexamethasone | 14 | $179 | $13 |
| Warfarin | 17 | $155 | $9 |
| Chlorhexidine Gluconate | 24 | $140 | $6 |
| Prednisone | 20 | $86 | $4 |
2013: 4 drugs
| Acyclovir | 68 | $734 | $11 |
| Dapsone | 22 | $702 | $32 |
| Dexamethasone | 26 | $255 | $10 |
| Chlorhexidine Gluconate | 11 | $67 | $6 |
Money from drug and device companies
$88,908 in 2025
| 2025 | 14 | 75 | $76,559 | $88,908 |
| 2024 | 17 | 94 | $75,119 | $96,599 |
| 2023 | 17 | 44 | $48,192 | $51,276 |
| 2022 | 12 | 28 | $35,710 | $37,247 |
| 2021 | 11 | 20 | $30,047 | $30,261 |
| 2020 | 10 | 37 | $57,039 | $64,232 |
| 2019 | 9 | 90 | $54,162 | $86,988 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Takeda Pharmaceuticals U.S.A. | Hyqvia | $22,079 | 4 payments
|
| Janssen Global Services | Darzalex | $15,854 | 24 payments
|
| AstraZeneca Pharmaceuticals LP | None | $9,208 | 5 payments
|
| Grifols Shared Services North America | None | $8,250 | 1 payment
|
| GlaxoSmithKline | None | $8,093 | 5 payments
|
| Abbvie | None | $5,075 | 1 payment
|
See all 61 published payments
| Janssen Global Services | Consulting · 2025-12-19 | Darzalex | $1,125 |
| Janssen Global Services | Meals · 2025-12-05 | Darzalex | $39 |
| Janssen Global Services | Meals · 2025-12-05 | Darzalex | $17 |
| Grifols Shared Services North America | Consulting · 2025-12-04 | None | $8,250 |
| Legend Biotech USA | Consulting · 2025-11-24 | Carvykti | $2,513 |
| Janssen Biotech | Meals · 2025-11-18 | None | $30 |
| Janssen Biotech | Meals · 2025-11-18 | None | $40 |
| Janssen Biotech | Meals · 2025-11-17 | None | $121 |
| Genentech | Consulting · 2025-11-06 | Venclexta | $760 |
| Janssen Biotech | Meals · 2025-10-22 | Darzalex | $75 |
| Janssen Global Services | Consulting · 2025-10-17 | Darzalex | $1,125 |
| Abbvie | Consulting · 2025-10-17 | None | $5,075 |
| Janssen Global Services | Consulting · 2025-10-03 | Darzalex | $3,750 |
| Janssen Scientific Affairs | Consulting · 2025-09-18 | Darzalex | $1,725 |
| Janssen Global Services | Meals · 2025-09-15 | Darzalex | $12 |
| Janssen Global Services | Travel · 2025-09-15 | Darzalex | $10 |
| Janssen Global Services | Travel · 2025-09-15 | Darzalex | $9 |
| Janssen Global Services | Meals · 2025-09-15 | Darzalex | $59 |
| Janssen Global Services | Travel · 2025-09-14 | Darzalex | $275 |
| Takeda Pharmaceuticals U.S.A. | Paid to speak or teach · 2025-07-21 | Hyqvia | $11,600 |
| Takeda Pharmaceuticals U.S.A. | Travel · 2025-07-21 | Hyqvia | $124 |
| Janssen Global Services | Consulting · 2025-07-07 | None | $705 |
| Janssen Global Services | Travel · 2025-07-03 | Darzalex | $240 |
| Janssen Global Services | Consulting · 2025-07-03 | Darzalex | $1,125 |
| Janssen Global Services | Consulting · 2025-07-03 | Darzalex | $1,125 |
| Janssen Global Services | Consulting · 2025-06-27 | Darzalex | $1,500 |
| Janssen Global Services | Meals · 2025-06-26 | Darzalex | $20 |
| GlaxoSmithKline | Consulting · 2025-06-25 | None | $2,800 |
| Kite Pharma | Consulting · 2025-06-17 | Tecartus | $1,800 |
| Janssen Global Services | Meals · 2025-06-14 | Darzalex | $21 |
| Janssen Global Services | Meals · 2025-06-14 | Darzalex | $14 |
| Takeda Pharmaceuticals U.S.A. | Travel · 2025-06-13 | Hyqvia | $841 |
| Janssen Global Services | Travel · 2025-06-12 | Darzalex | $65 |
| Janssen Global Services | Travel · 2025-06-12 | Darzalex | $30 |
| Janssen Global Services | Consulting · 2025-06-12 | Darzalex | $1,410 |
| Janssen Global Services | Meals · 2025-06-12 | Darzalex | $29 |
| GlaxoSmithKline | Meals · 2025-06-11 | None | $23 |
| GlaxoSmithKline | Meals · 2025-06-11 | None | $70 |
| Legend Biotech USA | Travel · 2025-06-09 | None | $7 |
| Legend Biotech USA | Meals · 2025-06-09 | None | $7 |
| Takeda Pharmaceuticals U.S.A. | Travel · 2025-06-06 | Hyqvia | $9,515 |
| Legend Biotech USA | Consulting · 2025-05-07 | Carvykti | $2,010 |
| Janssen Biotech | Consulting · 2025-05-05 | Talvey | $2,820 |
| Genentech | Consulting · 2025-04-24 | Venclexta | $380 |
| Kite Pharma | Consulting · 2025-04-24 | None | $2,910 |
| Genentech | Consulting · 2025-04-03 | Venclexta | $760 |
| Kite Pharma | Meals · 2025-03-27 | None | $125 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-03-26 | None | $107 |
| Sekisui Diagnostics | Gift · 2025-03-01 | None | $300 |
| GlaxoSmithKline | Consulting · 2025-02-25 | None | $4,000 |
| Pfizer | Meals · 2025-02-21 | Elrexfio | $47 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-02-20 | None | $6,560 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-14 | None | $35 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-14 | None | $45 |
| Regeneron Healthcare Solutions | Consulting · 2025-02-07 | None | $2,781 |
| Genentech | Consulting · 2025-02-06 | Venclexta | $380 |
| Janssen Global Services | Consulting · 2025-01-31 | Darzalex | $525 |
| GlaxoSmithKline | Consulting · 2025-01-30 | None | $1,200 |
| Janssen Global Services | Consulting · 2025-01-10 | Darzalex | $2,625 |
| Genentech | Consulting · 2025-01-08 | Venclexta | $760 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-01-02 | None | $2,460 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $96,599
| Takeda Pharmaceuticals U.S.A. | None | $33,544 | 6 payments
|
| Octapharma USA | Ivig | $13,231 | 18 payments
|
| Genzyme | Sarclisa | $10,891 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | None | $9,347 | 6 payments
|
| GlaxoSmithKline | None | $7,315 | 7 payments
|
| F. Hoffmann-La Roche AG | None | $6,080 | 2 payments
|
| Kite Pharma | None | $4,120 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | None | $3,768 | 1 payment
|
| Legend Biotech USA | Carvykti | $2,573 | 5 payments
|
| Karyopharm Therapeutics | Xpovio | $2,296 | 3 payments
|
| Celgene | None | $1,162 | 7 payments
|
| Janssen Global Services | Darzalex | $724 | 3 payments
|
| Janssen Research & Development | Carvykti | $703 | 6 payments
|
| Abbvie | Venclexta | $338 | 1 payment
|
| Sekisui Diagnostics | None | $250 | 1 payment
|
| Janssen Biotech | Darzalex | $198 | 3 payments
|
| AstraZeneca UK | Calquence | $60 | 1 payment
|
2023: $51,276
| Genzyme | Sarclisa | $21,524 | 12 payments
|
| Celgene | Pomalyst | $6,457 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | None | $4,881 | 3 payments
|
| Kite Pharma | Tecartus | $3,820 | 1 payment
|
| Amgen | Kyprolis | $3,220 | 1 payment
|
| F. Hoffmann-La Roche AG | None | $3,040 | 2 payments
|
| GlaxoSmithKline | None | $2,689 | 3 payments
|
| Adaptive Biotechnologies | Clonoseq | $2,400 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $1,514 | 3 payments
|
| AbbVie | Venclexta | $803 | 2 payments
|
| Sekisui Diagnostics | None | $275 | 1 payment
|
| Genentech USA | None | $163 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $130 | 1 payment
|
| Janssen Research & Development | None | $130 | 1 payment
|
| Janssen Biotech | Darzalex | $92 | 2 payments
|
| Legend Biotech USA | None | $79 | 2 payments
|
| Janssen Global Services | Carvykti | $59 | 2 payments
|
2022: $37,247
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $11,249 | 2 payments
|
| GlaxoSmithKline | None | $6,500 | 2 payments
|
| Janssen Biotech | Tecvayli | $4,834 | 6 payments
|
| Karyopharm Therapeutics | Xpovio | $3,300 | 2 payments
|
| Genzyme | Sarclisa | $3,086 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | None | $2,805 | 2 payments
|
| Adaptive Biotechnologies | Clonoseq | $2,400 | 1 payment
|
| Amgen | Kyprolis | $2,020 | 1 payment
|
| Abbvie | Venclexta | $533 | 5 payments
|
| Sekisui Diagnostics | None | $330 | 1 payment
|
| Celgene | Abecma | $125 | 1 payment
|
| Janssen Global Services | Carvykti | $65 | 2 payments
|
2021: $30,261
| GlaxoSmithKline | None | $7,150 | 3 payments
|
| AbbVie | None | $4,725 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $4,475 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $3,485 | 2 payments
|
| Epizyme | Tazverik | $2,363 | 1 payment
|
| Pfizer | None | $2,205 | 1 payment
|
| Secura Bio | Farydak | $1,900 | 2 payments
|
| Amgen | Kyprolis | $1,403 | 2 payments
|
| Janssen Biotech | Darzalex | $1,338 | 3 payments
|
| Genzyme | Sarclisa | $1,079 | 1 payment
|
| Celgene | None | $138 | 2 payments
|
2020: $64,232
| Takeda Pharmaceuticals U.S.A. | None | $13,777 | 6 payments
|
| Genzyme | Sarclisa | $13,528 | 3 payments
|
| Amgen | Kyprolis | $10,196 | 7 payments
|
| Celgene | Revlimid | $9,940 | 5 payments
|
| Karyopharm Therapeutics | Xpovio | $7,524 | 3 payments
|
| Secura Bio | Farydak | $3,811 | 7 payments
|
| Janssen Biotech | Darzalex | $2,309 | 3 payments
|
| Janssen Global Services | Darzalex | $1,515 | 1 payment
|
| Genentech | Venclexta | $1,320 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Empliciti | $311 | 1 payment
|
2019: $86,988
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $23,680 | 18 payments
|
| Amgen | Kyprolis | $20,975 | 25 payments
|
| Celgene | Revlimid | $17,561 | 13 payments
|
| Genzyme | Cd38 | $12,155 | 18 payments
|
| E.R. Squibb & Sons L.L.C. | Empliciti | $3,990 | 2 payments
|
| Janssen Scientific Affairs | Darzalex | $2,903 | 2 payments
|
| Janssen Global Services | Darzalex | $2,876 | 6 payments
|
| Secura Bio | Farydak | $1,602 | 2 payments
|
| Seattle Genetics | None | $1,248 | 4 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Janssen Research & Development, LLC · A Phase 1 First in Human Open Label Dose Escalation Study of Jnj64407564 A Humanized Gprc5d X Cd3 Duobody Antibody in Subjects With Relapsed Or Refractory Multiple Myeloma · 2021 | Their institution | $3,013,545 |
| Janssen Research & Development, LLC · A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Jnj-64407564, A Humanized Gprc5d X Cd3 Duobody Antibody, in Subjects With Relapsed Or Refractory Multiple Myeloma · 2020 | Their institution | $2,954,915 |
| Janssen Research & Development, LLC · A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma · 2022 | Their institution | $2,899,867 |
| Janssen Research & Development, LLC · A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Jnj-64407564, A Humanized Gprc5d X Cd3 Duobody Antibody, in Subjects With Relapsed Or Refractory Multiple Myeloma · 2019 | Their institution | $2,816,511 |
| Janssen Research & Development, LLC · A Phase 1 First in Human Open Label Dose Escalation Study of Jnj64407564 A Humanized Gprc5d X Cd3 Duobody Antibody in Subjects With Relapsed Or Refractory Multiple Myeloma · 2022 | Their institution | $2,182,633 |
| Janssen Research & Development, LLC · A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma · 2021 | Their institution | $1,726,094 |
| Amgen Inc. · A Phase I Study of the Combination of A Selective Inhibitor of Nuclear Export (Sine), Selinexor With Carfilzomib and Dexamethasone in Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma. · 2019 | Their institution | $928,560 |
| Amgen Inc. · A Multi-Arm Phase Ib Study of Sar650984 (Isatuximab, An Anti-Cd38 Mab) in Combination With Carfilzomib, High-Dose Carfilzomib and Dexamethasone, and Carfilzomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed Or Refractory Multiple Myel · 2019 | Their institution | $631,421 |
| Janssen Research & Development, LLC · A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma · 2023 | Their institution | $405,000 |
| Janssen Research & Development, LLC · A Phase 1 First in Human Open Label Dose Escalation Study of Jnj64007957 A Humanized Bcma X Cd3 Duobody Antibody in Subjects With Relapsed Or Refractory Multiple Myeloma · 2021 | Their institution | $333,379 |
| Janssen Research & Development, LLC · A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Jnj-64007957, A Humanized Bcma X Cd3 Duobody Antibody, in Subjects With Relapsed Or Refractory Multiple Myeloma · 2020 | Their institution | $321,109 |
| Celgene Corporation · Phase 1 in Rrmm - A Phase 1, Multi-Center, Open-Label, Dose Finding Study of Cc-92328 (Df3001), A Bcma Targeting Tri-Specific Natural Killer Cell Engager Therapy (Trinket), in Subjects With Relapsed and/Or Refractory Multiple Myeloma. · 2023 | Their institution | $290,202 |
| Janssen Research & Development, LLC · An Open-Label, Multicenter, Dose Escalation Phase 1b Study To Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab With the Addition of Recombinant Human Hyaluronidase (Rhuph20) for the Treatment of Subjects With Relapsed Or Refractory Multiple Myeloma · 2019 | Their institution | $268,079 |
| Janssen Research & Development, LLC · A Phase 1 First in Human Open Label Dose Escalation Study of Jnj64407564 A Humanized Gprc5d X Cd3 Duobody Antibody in Subjects With Relapsed Or Refractory Multiple Myeloma · 2023 | Their institution | $261,121 |
| GlaxoSmithKline, LLC. · A Phase II, Open Label, Randomized, Two-Arm Study To Investigate the E · 2019 | Their institution | $249,342 |
| Janssen Research & Development, LLC · A Phase 1 First in Human Open Label Dose Escalation Study of Jnj64007957 A Humanized Bcma X Cd3 Duobody Antibody in Subjects With Relapsed Or Refractory Multiple Myeloma · 2022 | Their institution | $236,843 |
| Janssen Research & Development, LLC · A Multi Arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma · 2022 | Their institution | $191,094 |
| Janssen Research & Development, LLC · A Multicenter Phase 2 Study To Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens · 2019 | Their institution | $179,444 |
| Janssen Research & Development, LLC · Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-Rvd) Versus Lenalidomide, Bortezomib, and Dexamethasone (Rvd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation · 2019 | Their institution | $150,292 |
| Janssen Research & Development, LLC · A Phase 2 Study of Daratumumab in Combination With Dose-Attenuated Bortezomib, Lenalidomide, and Dexamethasone in Elderly Newly Diagnosed Multiple Myeloma Patients · 2020 | Their institution | $146,553 |
| Celgene Corporation · Study To Evaluate the Safety and Tolerability of Cc-92328 in Participants With Relapsed and/Or Refractory Multiple Myeloma · 2024 | Their institution | $139,461 |
| Janssen Research & Development, LLC · A Multi Arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma · 2023 | Their institution | $135,521 |
| Celgene Corporation · Phase 1 in Rrmm - A Phase 1, Multi-Center, Open-Label, Dose Finding Study of Cc-92328 (Df3001), A Bcma Targeting Tri-Specific Natural Killer Cell Engager Therapy (Trinket), in Subjects With Relapsed and/Or Refractory Multiple Myeloma. · 2022 | Their institution | $128,564 |
| Janssen Research & Development, LLC · Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-Rvd) Versus Lenalidomide, Bortezomib, and Dexamethasone (Rvd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation · 2020 | Their institution | $108,057 |
| Janssen Research & Development, LLC · A Phase 2 Study of Daratumumab in Combination With Dose Attenuated Bortezomib Lenalidomide and Dexamethasone in Elderly Newly Diagnosed Multiple Myeloma Patients · 2021 | Their institution | $84,641 |
| Janssen Research & Development, LLC · An Open-Label, Multicenter, Dose Escalation Phase 1b Study To Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab With the Addition of Recombinant Human Hyaluronidase (Rhuph20) for the Treatment of Subjects With Relapsed Or Refractory Multiple Myeloma · 2020 | Their institution | $81,086 |
| Janssen Research & Development, LLC · Phase 2 Randomized Open Label Study Comparing Daratumumab Lenalidomide Bortezomib and Dexamethasone Drvd Versus Lenalidomide Bortezomib and Dexamethasone Rvd in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High Dose Chemotherapy and Autologo · 2021 | Their institution | $76,585 |
| Janssen Research & Development, LLC · A Multicenter Phase 2 Study To Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens · 2020 | Their institution | $69,421 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - the Insight - Mm Study · 2022 | Their institution | $68,583 |
| Janssen Research & Development, LLC · A Phase 1 First in Human Open Label Dose Escalation Study of Jnj64007957 A Humanized Bcma X Cd3 Duobody Antibody in Subjects With Relapsed Or Refractory Multiple Myeloma · 2023 | Their institution | $66,222 |
| Pharmacyclics LLC, an AbbVie Company · A Multicenter Phase 1/2b Study of the Brutons Tyrosine Kinase Inhibitor, Ibrutinib (Pci-32765), in Combination With Carfilzomib (Kyprolis) in Subjects With Relapsed Or Relapsed and Refractory Multiple Myeloma · 2021 | Their institution | $59,861 |
| Celgene Corporation · A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophospamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma · 2020 | Their institution | $52,358 |
| Janssen Research & Development, LLC · A Study To Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma · 2019 | Their institution | $47,172 |
| Seattle Genetics, Inc. · Phase 1 Study of Sgn-Cd48a in Patients With Relapsed Or Refractory Multiple Myeloma · 2019 | Their institution | $39,989 |
| GlaxoSmithKline, LLC. · A Phase II, Open Label, Randomized, Two-Arm Study To Investigate the E · 2023 | Their institution | $39,874 |
| Amgen Inc. · A Phase I Study of the Combination of A Selective Inhibitor of Nuclear Export (Sine), Selinexor With Carfilzomib and Dexamethasone in Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma. · 2021 | Their institution | $38,966 |
| Janssen Research & Development, LLC · Protocol - 54757414-Mmy-1001: An Open-Label, Multicenter, Phase 1b Study of Jnj-54767414 (Humax Cd38) (Anti-Cd38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma · 2019 | Their institution | $34,578 |
| Janssen Research & Development, LLC · Phase 1, First-in-Human, Dose Escalation Study of Jnj-79635322, A Trispecific Antibody, in Participants With Relapsed Or Refractory Multiple Myeloma · 2024 | Their institution | $34,338 |
| Janssen Research & Development, LLC · A Study To Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma · 2021 | Their institution | $32,453 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase I/II Study of the Addition of Ixazomib To Onc201 and Dexamethasone in Relapsed and/Or Refractory Multiple Myeloma · 2020 | Their institution | $31,057 |
| Janssen Research & Development, LLC · Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (Drd) Vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Or Refractory Multiple Myeloma · 2019 | Their institution | $28,015 |
| Takeda Pharmaceuticals U.S.A., Inc. · The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma Insight · 2019 | Their institution | $26,876 |
| Janssen Research & Development, LLC · A Multi Center Phase 2 Study To Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens · 2021 | Their institution | $25,649 |
| Janssen Research & Development, LLC · A Study To Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma · 2022 | Their institution | $25,444 |
| Janssen Research & Development, LLC · A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Jnj-64007957, A Humanized Bcma X Cd3 Duobody Antibody, in Subjects With Relapsed Or Refractory Multiple Myeloma · 2019 | Their institution | $22,590 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - the Insight - Mm Study · 2020 | Their institution | $21,987 |
| Array BioPharma Inc. · An Open-Label, Multicenter Rollover Study To Allow Continued Access To Filanesib (Arry-520) for Patients With Multiple Myeloma Who Are Currently Receiving Filanesib in Studies Sponsored By Array Biopharma Inc. · 2019 | Their institution | $21,078 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - the Insight - Mm Study · 2021 | Their institution | $20,264 |
| GlaxoSmithKline, LLC. · A Phase II, Open Label, Randomized, Two-Arm Study To Investigate the E · 2020 | Their institution | $18,968 |
| GlaxoSmithKline, LLC. · A Phase II, Open Label, Randomized, Two-Arm Study To Investigate the E · 2021 | Their institution | $18,688 |
| Janssen Research & Development, LLC · A Phase 3 Study Comparing Daratumumab . Lenalidomide and Dexamethasone (Drd) Versus Lenalidomide and Dexamethasone (Rd) in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Eligible for High Dose Chemotherapy and Autologous Stem Cell Transplant · 2019 | Their institution | $18,339 |
| Janssen Research & Development, LLC · A Study To Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma · 2020 | Their institution | $16,606 |
| Takeda Pharmaceuticals U.S.A., Inc. · An Open-Label, Dose-Escalation, Phase 1-2 Study of the Oral Formulation of Mln9708 Administered Twice-Weekly in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment · 2019 | This clinician | $14,887 |
| ARRAY BIOPHARMA INC · An Openlabel Multicenter Rollover Study To Allow Continued Access To Filanesib Array520 for Patients With Mulitple Myeloma Who Are Currently Receiving Filanesib in Studies Sponsored By Array Biopharma Inc · 2020 | Their institution | $14,563 |
| Janssen Research & Development, LLC · A Phase 3 Study Comparing Daratumumab . Lenalidomide and Dexamethasone (Drd) Versus Lenalidomide and Dexamethasone (Rd) in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Eligible for High Dose Chemotherapy and Autologous Stem Cell Transplant · 2020 | Their institution | $14,058 |
| GlaxoSmithKline, LLC. · A Phase II, Open Label, Randomized, Two-Arm Study To Investigate the E · 2022 | Their institution | $11,820 |
| Janssen Research & Development, LLC · Phase 2 Randomized Open Label Study Comparing Daratumumab Lenalidomide Bortezomib and Dexamethasone Drvd Versus Lenalidomide Bortezomib and Dexamethasone Rvd in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High Dose Chemotherapy and Autologous Stem Cell Transplantation · 2022 | Their institution | $9,445 |
| Janssen Research & Development, LLC · A Phase 2 Study of Daratumumab in Combination With Dose Attenuated Bortezomib Lenalidomide and Dexamethasone in Elderly Newly Diagnosed Multiple Myeloma Patients · 2022 | Their institution | $9,443 |
| Janssen Research & Development, LLC · Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (Drd) Vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Or Refractory Multiple Myeloma · 2020 | Their institution | $8,250 |
| Amgen Inc. · A Combination of Carfilzomib, Dexamethasone, and Daratumumab for Treatment of Adult Patients With Relapsed/Refractory Multiple Myeloma in Two Dosing Regimens: Once-Weekly and Twice-Weekly · 2021 | This clinician | $7,626 |
| Janssen Research & Development, LLC · A Phase 3 Study Comparing Daratumumab . Lenalidomide and Dexamethasone Drd Versus Lenalidomide and Dexamethasone Rd in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Eligible for High Dose Chemotherapy and Autologous Stem Cell Transplant · 2021 | Their institution | $6,325 |
| Janssen Research & Development, LLC · An Open Label Multi Center Dose Escalation Phase 1b Study To Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab With the Addition of Recombinant Human Hyaluronidase Rhuph20 for the Treatment of Subjects With Relapsed Or Refracto · 2021 | Their institution | $5,866 |
| Takeda Pharmaceuticals U.S.A., Inc. · The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma Insight · 2019 | This clinician | $5,211 |
| Amgen Inc. · B-Cell Maturation Antigen (Bcma) in Multiple Myeloma: Rationale for Targeting and Current Therapeutic Approaches · 2020 | This clinician | $4,146 |
| Janssen Research & Development, LLC · Phase 3 Study Comparing Daratumumab Lenalidomide and Dexamethasone Drd Vs Lenalidomide and Dexamethasone Rd in Subjects With Relapsed Or Refractory Multiple Myeloma · 2022 | Their institution | $3,600 |
| Taiho Oncology, Inc. · 2019 | Their institution | $3,250 |
| Seagen Inc. · Phase 1 Study of Sgn-Cd48a in Patients With Relapsed Or Refractory Multiple Myeloma · 2020 | Their institution | $3,175 |
| Janssen Research & Development, LLC · Phase 3 Study Comparing Daratumumab Lenalidomide and Dexamethasone Drd Vs Lenalidomide and Dexamethasone Rd in Subjects With Relapsed Or Refractory Multiple Myeloma · 2021 | Their institution | $3,050 |
| Celgene Corporation · A Phase 1, Multi-Center, Open-Label, Dose Finding Study of Cc-92328 (Df3001), A Bcma Targeting Tri-Specific Natural Killer Cell Engager Therapy (Trinket), in Subjects With Relapsed and/Or Refractory Multiple Myeloma. · 2025 | Their institution | $3,034 |
| Janssen Research & Development, LLC · A Multiarm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma · 2022 | Their institution | $3,000 |
| Janssen Research & Development, LLC · Protocol - 54757414-Mmy-1001: An Open-Label, Multicenter, Phase 1b Study of Jnj-54767414 (Humax Cd38) (Anti-Cd38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma · 2020 | Their institution | $2,756 |
| Janssen Research & Development, LLC · A Study To Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma · 2023 | Their institution | $2,596 |
| Amgen Inc. · Comparison of Efficacy Outcomes for Carfilzomib Plus Dexamethasone and Daratumumab (Kdd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (Pvd) and D-Pd in Relapsed Or Refractory Multiple Myeloma · 2021 | This clinician | $1,349 |
| Janssen Research & Development, LLC · A Phase 3 Study Comparing Daratumumab . Lenalidomide and Dexamethasone Drd Versus Lenalidomide and Dexamethasone Rd in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Eligible for High Dose Chemotherapy and Autologous Stem Cell Transplant · 2022 | Their institution | $503 |
| Amgen Inc. · Efficacy and Safety of Weekly Carfilzomib (70 Mg/M 2), Dexamethasone, and Daratumumab (Kdd70) Is Co · 2020 | This clinician | $463 |
| Amgen Inc. · Efficacy and Safety of Carfilzomib, Dexamethasone, and Daratumumab (Kdd) Twice-Weekly at 56 Mg/M2 An · 2020 | This clinician | $175 |
| Amgen Inc. · P3 Kd V Kdd in Relapsed/Refractory Mm (Candor) · 2020 | This clinician | $12 |
Professional record
- NPI
- 1376560136
- Licence
- NY 219311
- Trained
- University of California, Geffen School of Medicine, 1999 · 27 years ago
- Group
- UCSF Medical Group Business Services · University of California San Francisco · Regents of the University of California
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 400 Parnassus Ave, San Francisco, CA, 94143
- NPI first listed
- 2006-07-17
- NPI last updated
- 2024-01-21
- NPI record certified
- 2024-01-21
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 400 Parnassus Ave, San Francisco, CA, 94143